Skip to search formSkip to main contentSkip to account menu

Rebif

National Institutes of Health

Related topics

Related topics

4 relations

Broader (4)

Interferon beta-1aInterferon-betaRecombinant Interferon BetaRecombinant interferon beta-1a

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
[A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year…
AIM To prove the equivalent efficacy of teberif (BCD-033, interferon beta-1) and rebif (interferon beta-1a) in patients with… 
2016
2016
[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
OBJECTIVE to compare the results of treatment of multiple sclerosis (MS) with genfaxon, cinnovex and rebif. MATERIAL AND… 
2012
2012
[Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Authors have followed up 230 patients with multiple sclerosis treated with disease modifying drugs (DMD) using the data of the… 
2011
2011
Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients
2011
2011
277 A Rare Case of Rebif Induced Thrombotic Thrombocytopenic Purpura
A RARE CASE OF REBIF INDUCED THROMBOTIC THROMBOCYTOPENIC PURPURA Geetha Seerangan, Mozzam Sana, Nimrit Goraya Scott & White… 
2010
2010
Current Disease-Modifying Therapeutic Strategies in Multiple Sclerosis
Review
2008
Review
2008
of the clinical evidence for interferon β 1 a ( Rebif ® ) in the treatment of multiple sclerosis
Correspondence: Fabio Monzani Department of Internal Medicine, University of Pisa, Via Roma 67, 56126 Pisa, Italy Tel +39 050 993… 
2004
2004
Rationale and design of theprospective and retrospectiveobservational study of Avonexand Rebif (PROOF) for thetreatment of relapsing-remittingmultiple sclerosis
SUMMARY Previous studies comparing the two available interferon beta (IFNβ)-1a products, Avonex and Rebif, for the treatment of… 
2003
2003
[Results of a multicenter study of Rebif-22 mcg administration in Russia].
The results of multicenter study of Rebif 22 micrograms in Russia have been reported. 167 multiple sclerosis patients have… 
2003
2003
[Cost-utility analisys of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain].
OBJECTIVE To carry out a cost-utility analysis of the treatment of relapsing-remitting multiple sclerosis (RRMS) with glatiramer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)